Ziritaxestat is a small-molecule, selective autotaxin inhibitor that was investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF). Initially showing promise in early-phase studies, ziritaxestat underwent evaluation in two large-scale phase 3 clinical trials, ISABELA 1 and ISABELA 2.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.